Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

BACKGROUND: This investigator-initiated trial provided the justification for the phase III GRID study resulting in worldwide regulatory approval of regorafenib as a third-line therapy for patients with metastatic gastrointestinal stromal tumors (GIST). We report the genotype analyses, long-term safe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Ben-Ami, E., Barysauskas, C. M., von Mehren, M., Heinrich, M. C., Corless, C. L., Butrynski, J. E., Morgan, J. A., Wagner, A. J., Choy, E., Yap, J. T., Van den Abbeele, A. D., Solomon, S. M., Fletcher, J. A., Demetri, G. D., George, S.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279099/
https://ncbi.nlm.nih.gov/pubmed/27371698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw228
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados